Literature DB >> 8568122

Chemokines in seasonal allergic rhinitis.

P Kuna1, M Lazarovich, A P Kaplan.   

Abstract

Monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (MCAF/MCP-1), RANTES, and macrophage inflammatory protein (MIP)-1 alpha are chemokines known to activate basophils (MCAF/RANTES) and eosinophils (RANTES/MIP-1 alpha). IL-8 inhibits MCAF-induced histamine release from basophils. We questioned whether a relationship exists between the levels of these chemokines and various inflammatory mediators released from mast cells, eosinophils, and basophils as assessed in nasal secretions obtained from patients during the allergy season and out of season. Samples were assessed for MCAF/MCP-1, RANTES, MIP-1 alpha, IL-8, histamine, tryptase and eosinophil cationic protein (ECP) in three subject groups: subjects with allergic rhinitis (n = 18), atopic subjects without rhinitis (n = 9), and healthy individuals (n = 6). Statistically significant differences were apparent only in the subjects with symptoms as follows. MCAF/MCP-1 increased during the season from 336 +/- 47 pg/ml to 829 +/- 137 pg/ml (p < 0.001), whereas IL-8 decreased from a baseline of 1932 +/- 335 pg/ml to 1070 +/- 202 pg/ml (p < 0.028). The ratio of IL-8 to MCAF/MCP-1 decreased during the symptomatic season from the baseline of 6.66 +/- 1.06 seen during winter to 1.3 +/- 0.22 during ragweed season (p < 0.001). Histamine increased from 6.3 +/- 1.5 to 89 +/- 15.5 ng/ml (p < 0.001), ECP increased from 20.6 +/- 6.4 to 237.1 +/- 50.2 ng/ml (p < 0.001), and tryptase increased from 2.34 +/- 0.6 to 9.7 +/- 2.3 U/ml (p < 0.001). Most samples did not have detectable quantities of MIP-1 alpha or RANTES. We also found a correlation between the level of MCAF/MCP-1 and IL-8 and the level of histamine or IL-8 and ECP. Our results suggest that the chemokines MCAF/MCP-1 and IL-8 may participate in the pathogenesis of allergic rhinitis, contributing to the attraction of the proinflammatory cells and mediator release, which might be very important during the late phase of the allergic reaction. Furthermore, the ratio of certain chemokines, such as MCAF/MCP-1 and IL-8 may reflect the magnitude of the reaction, as does the presence of histamine and ECP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568122     DOI: 10.1016/s0091-6749(96)70288-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  Pro-inflammatory interleukins in middle ear effusions from atopic and non-atopic children with chronic otitis media with effusion.

Authors:  Beata Zielnik-Jurkiewicz; Wanda Stankiewicz-Szymczak
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-16       Impact factor: 2.503

Review 2.  Ebastine in context. Introduction.

Authors:  E Buendia
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Lower airway disease in asthmatics with and without rhinitis.

Authors:  Anne E Dixon; Danielle M Raymond; Benjamin T Suratt; Lorraine M Bourassa; Charles G Irvin
Journal:  Lung       Date:  2008-10-09       Impact factor: 2.584

4.  Ragweed-allergic subjects have decreased serum levels of chemokines CCL2, CCL3, CCL4 and CCL5 out of the pollen season.

Authors:  Zhivka Kostova; Tsvetelina Batsalova; Dzhemal Moten; Ivanka Teneva; Balik Dzhambazov
Journal:  Cent Eur J Immunol       Date:  2016-01-15       Impact factor: 2.085

Review 5.  Diagnosis and management of rhinitis.

Authors:  D Weldon
Journal:  Prim Care       Date:  1998-12       Impact factor: 2.907

6.  Allergic rhinitis is associated with thromboembolic disease in pregnancy.

Authors:  Chia-Ta Wu; Chien-Han Tsao; Kuan-Ting Chen; Yu-Tzu Lee; Min-Sho Ku
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

7.  Allergy Enhances Neurogenesis and Modulates Microglial Activation in the Hippocampus.

Authors:  Barbara Klein; Heike Mrowetz; Josef Thalhamer; Sandra Scheiblhofer; Richard Weiss; Ludwig Aigner
Journal:  Front Cell Neurosci       Date:  2016-06-28       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.